Evidence map›Paper›PMID 19358267›Full record

ArticleInternational journal of cancer2009

Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis.

Paolo Onori, Sharon DeMorrow, Eugenio Gaudio, Antonio Franchitto, Romina Mancinelli, Julie Venter, Shelley Kopriva, Yoshiyuki Ueno, Domenico Alvaro, Jennifer Savage and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in International journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 89 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. The role of tumour microenvironment: a new vision for cholangiocarcinoma.Journal of cellular and molecular medicine · 2019
    Review
  13. Article
  14. Phytochemicals in Skin Cancer Prevention and Treatment: An Updated Review.International journal of molecular sciences · 2018
    Review
  15. Propolis and Its Potential to Treat Gastrointestinal Disorders.Evidence-based complementary and alternative medicine : eCAM · 2018
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Paolo OnoriDepartment of Experimental Medicine, University of L'Aquila, L'Aquila, Italy.
Sharon DeMorrow
Eugenio Gaudio
Antonio Franchitto
Romina Mancinelli
Julie Venter
Shelley Kopriva
Yoshiyuki Ueno
Domenico Alvaro
Jennifer Savage
Gianfranco Alpini
Heather Francis
Texas A&M Health Science Center · USSapienza University of Rome · ITCentral Texas Veterans Health Care System · USTohoku University · JPUniversity of L'Aquila · IT

Funding

GROWTH REGULATION OF THE INTRAHEPATIC BILIARY TREER01DK054811 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ALPINI, GIANFRANCO D, GLASER, SHANNON STROUD · 2000 to 2021
$3.8M
Regulation of Bile Duct Growth in Bile Duct Ligated RatsR01DK062975 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ALPINI, GIANFRANCO D, GLASER, SHANNON STROUD · 2005 to 2014
$1.9M
Role of Sensory Neuropeptides in the Regulation of Biliary FunctionR01DK076898 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ALPINI, GIANFRANCO D, GLASER, SHANNON STROUD · 2008 to 2016
$1.8M
Endocannabinoid Regulation of Cholangiocarcinoma Cell GrowthK01DK078532 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DEMORROW, SHARON · 2007 to 2011
$697k
NIDDK NIH HHS DK054811NIDDK NIH HHS DK062975NIDDK NIH HHS DK078532NIDDK NIH HHS DK76898NIDDK NIH HHS K01 DK078532NIDDK NIH HHS R01 DK054811NIDDK NIH HHS R01 DK062975NIDDK NIH HHS R01 DK076898
6 · The paper itself

Abstract

Caffeic acid phenethyl ester (CAPE) inhibits the growth of tumor cells and is a known inhibitor of nuclear factor kappa beta (NF-kappaB), which is constitutively active in cholangiocarcinoma (CCH) cells. We evaluated the effects of CAPE on CCH growth both in vitro and in vivo. Inhibition of NF-kappaB DNA-binding activity was confirmed in nuclear extracts treated with CAPE at 50, 40 and 20 microM. CAPE decreases the expression of NF-kappaB1 (p50) and RelA (p65). CAPE decreased the growth of a number of CCH cells but not normal cholangiocytes. Cell cycle decrease was seen by a decrease in PCNA protein expression and the number of BrdU-positive cells treated with CAPE at 20 microM compared to vehicle. Inhibition of growth and increased cell cycle arrest of Mz-ChA-1 cells by CAPE were coupled with increased apoptosis. Bax expression was increased, whereas Bcl-2 was decreased in cells treated with CAPE compared to vehicle. In vivo studies were performed in BALB/c nude (nu/nu) mice implanted subcutaneously with Mz-ChA-1 cells and treated with daily IP injections of DMSO or CAPE (10 mg/kg body weight in DMSO) for 77 days. Tumor growth was decreased and tumor latency was increased 2-fold in CAPE compared to vehicle-treated nude mice. In tumor samples, decreased CCH growth by CAPE was coupled with increased apoptosis. CAPE both in vivo and in vitro decreases the growth of CCH cells by increasing apoptosis. These results demonstrate that CAPE might be an important therapeutic tool in the treatment of CCH.

Indexed as

AnimalsApoptosisbcl-2-Associated X ProteinBile Duct NeoplasmsBile Ducts, IntrahepaticBiomarkers, TumorCaffeic AcidsCell CycleCholangiocarcinomaCytotoxinsDimethyl SulfoxideDNADown-RegulationGene Expression Regulation, NeoplasticGenes, bcl-2HumansBAX protein, humanbcl-2-Associated X ProteinBiomarkers, Tumorcaffeic acid phenethyl esterCaffeic AcidsCytotoxinsDimethyl SulfoxideDNANF-kappa BPhenylethyl AlcoholProliferating Cell Nuclear AntigenTranscription Factor RelA

Identifiers

PMID19358267
PMCPMC3051346
OpenAlexW1973168828

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.